TG Therapeutics logo
TG Therapeutics
TGTX | NASDAQ
Chart Builder DCF Calculator
$62.76
-$1.75 (-2.71%)
At close: Nov 16, 2026, 4:00 PM ET
$62.74
-$0.02 (-0.03%)
After-hours: Nov 16, 2026, 7:30 PM ET

TG Therapeutics Company Profile

Company profile explained

Company Profile

Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.

Key Executives

Name Position
Michael S. Weiss Chairman, Chief Executive Officer & President
Sean A. Power Chief Financial Officer, Corporate Secretary & Treasurer
Adam Waldman Chief Commercialization Officer
Jenna Bosco Senior Vice President of Corporate Communications

Latest SEC Filings

Date Type Title
Oct 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Sep 14, 2026 4 Filing
Aug 07, 2026 4 Filing
Aug 05, 2026 10-Q Quarterly Report
Aug 03, 2026 8-K Current Report
Jun 15, 2026 4 Filing
Jun 15, 2026 4 Filing
Jun 15, 2026 4 Filing
Jun 15, 2026 4 Filing
Jun 15, 2026 4 Filing
View All SEC Filings ➞
TG Therapeutics
TG Therapeutics logo
Country United States
IPO Date May 3, 2010
Industry Biotechnology
Sector Healthcare
Employees 399
CEO Michael S. Weiss

Contact Details

3020 Carrington Mill Blvd. Morrisville, New York 27560 United States

Stock Details

Ticker Symbol TGTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001001316
CUSIP Number 88322Q108
ISIN Number US88322Q1085
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.